MX2025010791A - Compuesto triciclico - Google Patents

Compuesto triciclico

Info

Publication number
MX2025010791A
MX2025010791A MX2025010791A MX2025010791A MX2025010791A MX 2025010791 A MX2025010791 A MX 2025010791A MX 2025010791 A MX2025010791 A MX 2025010791A MX 2025010791 A MX2025010791 A MX 2025010791A MX 2025010791 A MX2025010791 A MX 2025010791A
Authority
MX
Mexico
Prior art keywords
tricyclic compound
compound
agonist
agonist activity
potent
Prior art date
Application number
MX2025010791A
Other languages
English (en)
Spanish (es)
Inventor
Nobukazu OHTA
Seiji Ogawa
Hiroshi Tokura
Yuji Yamazaki
Tetsuya Kitayama
Yuko Ube
Kouki MAKITANI
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2025010791A publication Critical patent/MX2025010791A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2025010791A 2023-03-13 2025-09-12 Compuesto triciclico MX2025010791A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023038845 2023-03-13
PCT/JP2024/009559 WO2024190777A1 (ja) 2023-03-13 2024-03-12 三環性化合物

Publications (1)

Publication Number Publication Date
MX2025010791A true MX2025010791A (es) 2025-10-01

Family

ID=92755170

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025010791A MX2025010791A (es) 2023-03-13 2025-09-12 Compuesto triciclico

Country Status (9)

Country Link
EP (1) EP4682141A1 (https=)
JP (1) JPWO2024190777A1 (https=)
KR (1) KR20260011665A (https=)
CN (1) CN120752225A (https=)
AU (1) AU2024235437A1 (https=)
IL (1) IL323168A (https=)
MX (1) MX2025010791A (https=)
TW (1) TW202440095A (https=)
WO (1) WO2024190777A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120774781B (zh) * 2025-09-11 2025-12-02 阜新瑞宁化工有限公司 一种6,6,6-三氟己烷-2-酮的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2335490C2 (ru) * 2003-02-07 2008-10-10 Оно Фармасьютикал Ко., Лтд. Соединения карбоновой кислоты, фармацевтическая композиция на их основе, способ лечения и применение
CN101076531A (zh) * 2004-10-12 2007-11-21 解码遗传学公司 用于阻塞性血管疾病的羧酸迫位取代的双环化合物
WO2006090850A1 (ja) * 2005-02-25 2006-08-31 Ono Pharmaceutical Co., Ltd. ベンズアミド化合物
EP3237401B1 (en) * 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor

Also Published As

Publication number Publication date
IL323168A (en) 2025-11-01
WO2024190777A1 (ja) 2024-09-19
EP4682141A1 (en) 2026-01-21
AU2024235437A1 (en) 2025-09-25
CN120752225A (zh) 2025-10-03
TW202440095A (zh) 2024-10-16
JPWO2024190777A1 (https=) 2024-09-19
KR20260011665A (ko) 2026-01-23

Similar Documents

Publication Publication Date Title
MX2025010791A (es) Compuesto triciclico
CO2025009073A2 (es) Compuestos cíclicos fusionados y uso de los mismos
CO2022009538A2 (es) Arn guía antisentido con región funcional añadida para editar arn blanco
CL2022001492A1 (es) Nuevos inhibidores de braf como rompedores de la paradoja
CL2024003354A1 (es) Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras
CL2024000373A1 (es) Compuesto inductor de la degradación de plk1 novedoso
GT200900097A (es) Inhibidores de la proteasa ns3 del hcv.
CL2020002696A1 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
DOP2019000225A (es) Compuestos sulfamida cíclicos y métodos de uso de los mismos
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CL2023003154A1 (es) Compuestos heterocíclicos
MX2012001654A (es) Metodos para usar moduladores de c-met.
CL2023000594A1 (es) Compuestos heterocíclicos
ECSP21001265A (es) Compuestos heterocíclicos antihelmínticos
CO2020003114A2 (es) Compuesto que tiene estructura ciclica
AR106670A1 (es) Compuestos que contienen azufre para usar como solventes
CR20120285A (es) Método de manejo de bananas
MX2022007634A (es) Inhibidores de egfr.
ECSP20080258A (es) Antidegradante de caucho de acción prolongada y composición de caucho que lo comprende para neumáticos
CO6700872A2 (es) Derivados de 1,4-oxazepano
CO2024003094A2 (es) Compuesto imidazocíclico y aplicación del mismo
CO2023012574A2 (es) Nuevos derivados de tiazolopirimidinona
MX2021008942A (es) Metodos para mitigar efectos toxicos vesicantes y gas caustico.
CO2025007845A2 (es) Sistemas y métodos para la operación de una línea eléctrica aérea
AR114782A1 (es) Disco híbrido